Revolutionary material science innovation,
OSSIOfiber® continues to evolve standard of care in orthopedic
surgery
OSSIO, Inc., a fast-growing medical technology company focused
on evolving orthopedic surgery with bio-integrative fixation
implants that leave no permanent implant behind, recently expanded
its offering with the launch of OSSIOfiber® small compression
staples for use in both hand and foot procedures, especially for
bunion repair with a surgical technique known as the Akin
osteotomy.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240619800123/en/
OSSIOfiber Small Compression Staple &
Inserter
Bradley Lamm, DPM, director of the Foot and Ankle Deformity
Center at the Paley Institute in West Palm Beach, Fla., and Selene
Parekh, MD, a professor of orthopedic surgery specializing in foot
and ankle procedures at the Rothman Institute in Princeton, N.J.,
and Philadelphia, were among the first clinicians to use the new
staples in an Akin bunion procedure.
“By design, OSSIOfiber small compression staples are remarkably
easy to insert during Akin bunion repair,” said Dr. Lamm. “This new
OSSIOfiber product line increases the opportunities for surgeons to
use a cutting-edge fixation technology that is replaced by bone
over time, without the inherent risks of metal implants. Patients
appreciate the no-metal footprint just as much as we surgeons
do.”
Dr. Parekh added: “I have used several different small
compression staples during my many years as a foot and ankle
surgeon. For me, the most important reason to use OSSIOfiber
bio-integrative implants in orthopedic surgery is the opportunity
to dispense with metal without sacrificing compression strength.
Not having to worry about hardware irritation after an Akin bunion
repair and the need for a secondary surgery is extremely attractive
to patient and surgeon alike.”
OSSIOfiber Portfolio Expansion
Cleared by the U.S. Food and Drug Administration (FDA) in
November 2023, OSSIOfiber small compression staples ― the company’s
latest offering for orthopedic fixation ― expands the company’s
product portfolio, which already includes larger compression
staples, as well as suture anchors, compression screws, trimmable
fixation nails and a hammertoe fixation system.
All OSSIOfiber implants are made with the same bio-integrative
fiber matrix, a revolutionary advance in material science.
Combining this highly differentiated technology with exceptional
instrumentation, OSSIOfiber small compression staples were
intentionally designed for ease of use, for compression strength
that matches or exceeds nitinol staples, and with all the
advantages of a non-permanent implant that patients prefer.
“Our mission at OSSIO is nothing less than transforming the
experience of patients who must undergo orthopedic surgery where
internal fixation is required,” said OSSIO CEO Brian Verrier. “With
more than 40,000 OSSIOfiber implants performed to date, just five
years since commercializing our first product in 2019, we launch
this new small compression staple platform, further expanding
patient access to a metal-free alternative for orthopedic
fixation.”
OSSIOfiber small compression staples are indicated for fixation
of arthrodesis, osteotomies, and fractures in hand or foot surgery
in the presence of appropriate brace and/or immobilization. The
number and size of the OSSIOfiber staples must be adapted to the
indication.
Intelligent Bone Regeneration Technology
OSSIOfiber relies on Intelligent Bone Regeneration Technology, a
breakthrough in fixation material that provides the first credible
solution to the shortcomings of permanent metal hardware,
conventional absorbable and allograft implants, combining
unparalleled mechanical strength and natural bone healing in a
non-permanent implant. Made from a proprietary mineral fiber matrix
held together by a bio-friendly polymer, OSSIOfiber implants
feature bio-integrative material properties that provide surgeons
with a more biologically friendly way to restore patients’
stability and mobility while leaving nothing permanent behind.
Designed for rapid bone in-growth, regeneration and replacement,
OSSIOfiber Intelligent Bone Regeneration Technology is a
first-of-its-kind implant material stronger than cortical bone. It
is engineered to provide the strength required for functional
fixation while allowing for full integration into patients’ native
anatomy without adverse biological response and can address many
surgical applications through the manufacturing of endless implant
designs, including nails, screws, staples, anchors and plates.
Looking ahead, OSSIO intends to pursue multiple applications for
OSSIOfiber implants in all major segments of orthopedics, such as
foot and ankle, hand and wrist, upper extremity and trauma,
pediatrics, sports medicine and reconstruction.
Notably for U.S. healthcare providers and payors, OSSIOfiber
implants utilize existing reimbursement codes and surgical
techniques.
About OSSIO
OSSIO is an orthopedic fixation company committed to
transforming the surgical experience for patients, physicians,
providers and payors. Founded in 2014, the company’s vision is to
provide the first credible replacement for metal implants in the
multibillion-dollar global orthopedic fixation market with
OSSIOfiber Intelligent Bone Regeneration Technology.
For more information on OSSIOfiber implants and OSSIO, which has
development headquarters in Caesarea, Israel, and commercial
headquarters in Woburn, Mass., visit www.ossio.io.
DISCLAIMER
Forward-looking statements contained herein are based on
estimates and assumptions of OSSIO management and are believed to
be reasonable, though they are inherently uncertain and difficult
to predict.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240619800123/en/
Joe McGrath Scope Strategic Communications
contactmcgrath@gmail.com +1-612-819-6421